These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 2437327)

  • 1. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.
    Ho DD; Sarngadharan MG; Hirsch MS; Schooley RT; Rota TR; Kennedy RC; Chanh TC; Sato VL
    J Virol; 1987 Jun; 61(6):2024-8. PubMed ID: 2437327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies and the course of HIV-induced disease.
    Wendler I; Bienzle U; Hunsmann G
    AIDS Res Hum Retroviruses; 1987; 3(2):157-63. PubMed ID: 3650100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.
    Robert-Guroff M; Aldrich K; Muldoon R; Stern TL; Bansal GP; Matthews TJ; Markham PD; Gallo RC; Franchini G
    J Virol; 1992 Jun; 66(6):3602-8. PubMed ID: 1374810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.
    Ho DD; Kaplan JC; Rackauskas IE; Gurney ME
    Science; 1988 Feb; 239(4843):1021-3. PubMed ID: 2830667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
    Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
    Broliden PA; von Gegerfelt A; Clapham P; Rosen J; Fenyö EM; Wahren B; Broliden K
    Proc Natl Acad Sci U S A; 1992 Jan; 89(2):461-5. PubMed ID: 1370580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.
    Klasse PJ; Pipkorn R; Blomberg J
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5225-9. PubMed ID: 2455899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable and conserved neutralization antigens of human immunodeficiency virus.
    Weiss RA; Clapham PR; Weber JN; Dalgleish AG; Lasky LA; Berman PW
    Nature; 1986 Dec 11-17; 324(6097):572-5. PubMed ID: 2431324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Palker TJ; Clark ME; Langlois AJ; Matthews TJ; Weinhold KJ; Randall RR; Bolognesi DP; Haynes BF
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1932-6. PubMed ID: 2450351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope.
    Palker TJ; Matthews TJ; Clark ME; Cianciolo GJ; Randall RR; Langlois AJ; White GC; Safai B; Snyderman R; Bolognesi DP
    Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2479-83. PubMed ID: 2436231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae.
    Barr PJ; Steimer KS; Sabin EA; Parkes D; George-Nascimento C; Stephans JC; Powers MA; Gyenes A; Van Nest GA; Miller ET
    Vaccine; 1987 Jun; 5(2):90-101. PubMed ID: 3300079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of serum neutralization response to the human immunodeficiency virus (HIV).
    Groopman JE; Benz PM; Ferriani R; Mayer K; Allan JD; Weymouth LA
    AIDS Res Hum Retroviruses; 1987; 3(1):71-85. PubMed ID: 2441727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of HIV envelope specific antibodies by immunoelectron microscopy and correlation with antibody titer and virus neutralizing activity.
    Hausmann EH; Gelderblom HR; Clapham PR; Pauli G; Weiss RA
    J Virol Methods; 1987 May; 16(1-2):125-37. PubMed ID: 3038935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
    Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
    J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.
    Skinner MA; Langlois AJ; McDanal CB; McDougal JS; Bolognesi DP; Matthews TJ
    J Virol; 1988 Nov; 62(11):4195-200. PubMed ID: 2845130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
    Nara PL; Robey WG; Arthur LO; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC; Fischinger PJ
    J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
    Palker TJ; Matthews TJ; Langlois A; Tanner ME; Martin ME; Scearce RM; Kim JE; Berzofsky JA; Bolognesi DP; Haynes BF
    J Immunol; 1989 May; 142(10):3612-9. PubMed ID: 2469721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies to gp110 and gp41 of human immunodeficiency virus.
    Gosting LH; McClure J; Dickinson ES; Watanabe SM; Shriver K; Goldstein LC
    J Clin Microbiol; 1987 May; 25(5):845-8. PubMed ID: 2438302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.
    Robey WG; Arthur LO; Matthews TJ; Langlois A; Copeland TD; Lerche NW; Oroszlan S; Bolognesi DP; Gilden RV; Fischinger PJ
    Proc Natl Acad Sci U S A; 1986 Sep; 83(18):7023-7. PubMed ID: 3018753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.
    Ranki A; Weiss SH; Valle SL; Antonen J; Krohn KJ
    Clin Exp Immunol; 1987 Aug; 69(2):231-9. PubMed ID: 3652531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.